高级检索

基于CCL2/CCR2信号轴的肿瘤免疫治疗药物的研究进展

Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis

  • 摘要: 趋化因子配体2(C-C motif chemokine ligand 2,CCL2)及其受体CCR2与肿瘤的发生、发展密切相关。CCL2/CCR2信号轴通过多种机制促进肿瘤进展,一方面CCL2与肿瘤细胞表面的CCR2结合促进肿瘤的生长/存活和转移;更为重要的是CCL2可以招募多种免疫抑制细胞在肿瘤微环境中聚集,抑制免疫细胞的功能和活性,促进肿瘤进展。本文综述了CCL2/CCR2信号轴以及其在肿瘤及肿瘤微环境中的作用,并重点介绍了靶向CCL2/CCR2信号轴药物的临床研究进展,以期深入并全面了解CCL2/CCR2信号轴在肿瘤进展中的作用机制,开发更有效的肿瘤免疫治疗药物。

     

    Abstract: C-C motif chemokine ligand 2 (CCL2) and its receptor CCR2 are closely related to tumorigenesis and tumor progression. The CCL2/CCR2 signaling axis promotes tumor progression through multiple mechanisms: CCL2 binds to CCR2 on the surface of tumor cells, and thus promotes tumor growth/survival and metastasis; more importantly, CCL2 recruits a variety of immunosuppressive cells to aggregate in the tumor microenvironment, and inhibits the function and activity of immune cells, promoting tumor progression. The article reviews the CCL2/CCR2 signaling axis and its role in tumors and tumor microenvironment, with particular focus on the advances in clinical research on drugs targeting CCL2/CCR2 signaling axis, in order to gain an in-depth and overall understanding of the mechanism of action of CCL2/CCR2 axis in tumor progression and develop more effective anti-tumor immunotherapeutic agents.

     

/

返回文章
返回